Open AccessGlibenclamide, a diabetic drug, prevents acute radiation-induced liver injury of mice via up-regulating intracellular ROS and subsequently activating Akt-NF-κB pathway
Author(s) -
Hu Liu,
Wei Wang,
Weihong Zhao,
Ziyun Huang,
Wei You Chen,
Yue Yang,
Jianguo Cui,
Cong Liu,
Hainan Zhao,
Jiaming Guo,
Pei Zhang,
Guosheng Fu,
Bailong Li,
Jianming Cai
Publication year - 2017
Publication title -
oncotarget
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.373
H-Index - 127
ISSN - 1949-2553
DOI - 10.18632/oncotarget.16501
Subject(s) - glibenclamide , reactive oxygen species , pharmacology , liver injury , protein kinase b , apoptosis , intracellular , medicine , cancer research , chemistry , diabetes mellitus , biology , endocrinology , microbiology and biotechnology , biochemistry
Acute radiation-induced liver injury is a limitation for hepatoma radiotherapy. Come so far the clinical treatments are insufficient. The effective, specific, low toxicity and novel drugs are in powerful need. Glibenclamide is a common hypoglycemic. Some studies have revealed its relation with intracellular reactive oxygen species, the crucial mediator to radiation injury. This study is aimed to investigate if glibenclamide could act on the acute radiation-induced liver injury.